Wet Age-related Macular Degeneration
56
5
10
27
Key Insights
Highlights
Success Rate
82% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
10.7%
6 terminated out of 56 trials
81.8%
-4.7% vs benchmark
25%
14 trials in Phase 3/4
37%
10 of 27 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 27 completed trials
Clinical Trials (56)
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
MMP-9 Inhibition for Recalcitrant Wet AMD
Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]
A Study to Compare JL14002 to Lucentis® in Subjects With Wet Age-related Macular Degeneration (wAMD)
User-centric Study of Patients' Receptiveness Towards the Web-based Automated Vision Impairment Gaze-tracking Analysis Systems
Automated Vision Assessment and Impairment Detection Through Gaze Analysis in Wet AMD Patients
Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD
Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)
Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)
Evaluating the Safety and Preliminary Efficacy of EXG202 Gene Therapy for Neovascular AMD
A Long-term Follow up Study of EXG102-031 in Participants With wAMD
AAVCAGsCD59 for the Treatment of Wet AMD
To Evaluate the Safety and Preliminary Efficacy of Intravitreal EXG202 Injection in Patients with Wet (neovascular) Age-related Macular Degeneration (wAMD)
Comparing Efficacy of 8-Week and 12-Week Faricimab Initial Follow-Up Treatment Intervals
Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease
RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
Clinical Study on the Efficacy and Safety of BAT5906 Injection